Market›Norepinephrine–dopamine reuptake inhibitor
Company Profile

Norepinephrine–dopamine reuptake inhibitor

A norepinephrine–dopamine reuptake inhibitor (NDRI) is a type of drug that inhibits the reuptake of the monoamine neurotransmitters norepinephrine and dopamine and thereby increases extracellular levels of these neurotransmitters and noradrenergic and dopaminergic neurotransmission. They work by competitively and/or noncompetitively inhibiting the norepinephrine transporter (NET) and dopamine transporter (DAT).

List of NDRIs
Many NDRIs exist, including the following: Some NDRIs, such as methylphenidate, may not act as simple NDRIs but rather as DAT "inverse agonists" (and possibly also analogously at the NET as well). If this theory is correct, then methylphenidate and other agents like cocaine may not be acting primarily as monoamine reuptake inhibitors but instead as robust monoamine releasing agent-esque drugs, albeit via a different mechanism of action than conventional substrate-type monoamine releasing agents. ==See also==
Source: Wikipedia ↗
tickerdossier.comtickerdossier.substack.com